SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
NEW YORK, Aug. 10, 2017 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conference:
- 2017 Wedbush PacGrow Healthcare Conference on August 16, 2017 at 9:10 a.m. Eastern Time
Webcast information for this event will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.
CONTACT: For more information about Intercept Pharmaceuticals, please contact: Intercept Pharmaceuticals: Mark Vignola +1-646-747-1000 [email protected] Media inquiries: [email protected] Investor inquiries: [email protected]
